EMEA: Physicians should not prescribe Acomplia (rimonabant)
The European Medicines Agency recommends suspension of the marketing authorisation of Acomplia The European Medicines Agency (EMEA) has recommended the suspension of the marketing authorisation for Acomplia (rimonabant) from Sanofi-Aventis. The EMEA’s Committee for Medicinal Products for Human Use (CHMP) has concluded that the benefits of Acomplia no longer outweigh its risks and the marketing authorisation […]